Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Upheaval in the chronic kidney disease market ranging from FDA’s ongoing re-evaluation of the safety of erythropoietin stimulating agents to impending major changes in Medicare reimbursement for dialysis patients is resulting in a chain reaction of adjustments in drug development strategies.

You may also be interested in...



Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger

The $18-per-share offer represents a 25% premium over AMAG's stock price as of Aug. 2, but it's not enough to return the anemia drug maker's valuation to the days just before it unveiled the Allos deal on July 20.

Seeking To Broaden Market For Feraheme, AMAG Runs Afoul Of DDMAC

The prospect of anemic Medicare compensation for Feraheme (ferumoxytol) may have pushed the company to promote the drug in ways that FDA's advertising reviewers think is illegitimate.

So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd

Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel